Cell and gene therapy (CGT) has entered a new era. The FDA approved seven new cell and gene therapies in 2024–2025, including Abeona’s ZEVASKYN and Novartis’s ITVISMA. These curative treatments are no longer science fiction – they are reaching patients. But here is the problem that smart investors are watching closely: manufacturing is failing.

The highly demand and sought after sales leadership training class by Dr. TiehKoun Koh from NY Kingfisher Associates.